Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trial Diversity Requires Community-Based Research Infrastructure, US FDA’s Woodcock Says

Executive Summary

COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.

You may also be interested in...



Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions

Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.

Clinical Research Needs To Move ‘Out Of The Ivory Tower,’ FDA’s Woodcock Urges

Acting Commissioner says she is ‘really going to be pushing’ to have clinical trials conducted in the community. CDER’s Cavazzoni and CBER’s Marks discuss master protocols, decentralized trials, and real world evidence at DIA’s annual meeting.

Clinical Trial Diversity: We Must ‘Turn This Moment Into A Movement’

Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel